|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM178212202 |
| 003 |
DE-627 |
| 005 |
20250209073914.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2008 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2008.01.016
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0594.xml
|
| 035 |
|
|
|a (DE-627)NLM178212202
|
| 035 |
|
|
|a (NLM)18337176
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Charles-Schoeman, Christina
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis
|
| 264 |
|
1 |
|c 2008
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 24.06.2008
|
| 500 |
|
|
|a Date Revised 24.11.2016
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a To evaluate the therapeutic potential of an apolipoprotein A-1 (apoA-1) mimetic peptide, D-4F, in combination with pravastatin in collagen-induced arthritis (CIA), syngeneic Louvain rats were immunized with type II collagen and randomized to vehicle control, D-4F monotherapy, pravastatin monotherapy, or D-4F + pravastatin combination therapy. Clinical arthritis activity was evaluated and radiographs, type II collagen antibody titers, cytokine/chemokine levels, and HDL function analysis were obtained. There was significant reduction in clinical severity scores in the high and medium dose D-4F + pravastatin groups compared to controls (p< or =0.0001). Reduction in erosive disease occurred in the medium/high dose combination groups compared to non-combination groups (p< or =0.01). Favorable changes in cytokines/chemokines were noted with treatment, and response to combination D-4F/pravastatin therapy was associated with improvement in HDL's anti-inflammatory properties. Combination D-4F/pravastatin significantly reduced clinical disease activity in CIA, and may have dual therapeutic potential in other autoimmune diseases with increased cardiovascular morbidity and mortality
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antibodies
|2 NLM
|
| 650 |
|
7 |
|a Anticholesteremic Agents
|2 NLM
|
| 650 |
|
7 |
|a Apolipoprotein A-I
|2 NLM
|
| 650 |
|
7 |
|a Cholesterol, HDL
|2 NLM
|
| 650 |
|
7 |
|a Collagen Type II
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a D-4F peptide
|2 NLM
|
| 650 |
|
7 |
|a Pravastatin
|2 NLM
|
| 650 |
|
7 |
|a KXO2KT9N0G
|2 NLM
|
| 700 |
1 |
|
|a Banquerigo, Mona Lisa
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hama, Susan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Navab, Mohamad
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Park, Grace S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Van Lenten, Brian J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wagner, Alan C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fogelman, Alan M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Brahn, Ernest
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 127(2008), 2 vom: 15. Mai, Seite 234-44
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:127
|g year:2008
|g number:2
|g day:15
|g month:05
|g pages:234-44
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2008.01.016
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 127
|j 2008
|e 2
|b 15
|c 05
|h 234-44
|